ResMed (RMD.AX ASX) Q2 beats lift A$36.82 intraday 30 Jan 2026: watch margins
RMD.AX stock jumped after ResMed Inc. reported stronger Q2 results, confirming demand for sleep and respiratory devices. The company posted GAAP earnings of A$392.59 million and EPS of A$2.68, with revenue up to A$1.422 billion, a 10.90% year-on-year increase. Intraday on 30 Jan 2026 the ASX-listed share is trading at A$36.82, range A$36.67–A$37.17, with volume 850344.00. Investors should watch margin trends and software subscription growth for signs of sustainable earnings momentum.
Earnings recap: RMD.AX stock Q2 results
ResMed’s Q2 showed adjusted earnings of A$411.47 million or A$2.81 per share, ahead of prior-year figures and close to Street expectations. Revenue of A$1.422 billion rose 10.90% year over year, led by device and masks sales and steady SaaS growth. Analysts flagged the revenue beat and margin expansion as the primary drivers behind the intraday price stability.
Reaction and price action: RMD.AX stock intraday moves
On the ASX the stock opened at A$36.80 and is trading at A$36.82, near the 50-day average A$37.57 and below the 200-day average A$39.51. Volume of 850344.00 compares with an average of 1060834.00, showing muted intraday participation. The one-day technical picture (RSI 48.63, MACD histogram 0.05) suggests range-bound trading after the earnings release.
Financials and valuation: RMD.AX stock metrics
Key metrics show EPS A$1.40 and a trailing PE of 26.00, with market cap A$53.13 billion. ResMed reports strong margins (net margin 27.35%) and return on equity 25.13%, supported by low leverage (debt/equity 0.14) and a current ratio 2.89. The company generates free cash flow per share A$12.04, supporting a dividend yield near 0.95% and buyback flexibility.
Meyka grade and forecast: RMD.AX stock outlook
Meyka AI rates RMD.AX with a score of 76.45 out of 100 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12‑month target of A$44.22, implying an upside of 20.11% from the current A$36.82; forecasts are model-based projections and not guarantees.
Risks and opportunities: RMD.AX stock analysis
Opportunities include recurring revenue from software and expansion in international mask adoption, while risks include competitive pressure, reimbursement changes, and supply chain costs. Institutional buying, such as AustralianSuper increasing holdings, supports conviction, but investors should monitor margin trends and any slowdown in device bookings.
Technical pulse: RMD.AX stock trading signals
Short-term indicators are neutral-to-cautious: ADX 16.55 shows no clear trend and ATR 0.64 points to low volatility. Bollinger Bands sit A$35.46–A$38.63, suggesting a tight trading band. A break above A$39.51 (200-day) would turn momentum constructive, while a drop below A$36.67 risks a pullback toward the 52-week low A$32.04.
Final Thoughts
ResMed’s Q2 beat confirms demand resilience in sleep and respiratory devices and supports the ASX listing at A$36.82 on 30 Jan 2026. RMD.AX stock shows solid fundamentals: revenue growth 10.90%, net margin 27.35%, ROE 25.13%, and low leverage (debt/equity 0.14). Analysts and institutional buyers lifted estimates ahead of the report, and our model sees a reasonable path to a A$44.22 12‑month target, implying 20.11% upside from the current price; forecasts are model-based projections and not guarantees. From a portfolio perspective, the healthcare sector remains defensive versus cyclicals, and ResMed offers a combination of growth and cash flow that fits income-growth allocations. Monitor device bookings, mask ASPs, and software subscription cadence as the next set of catalysts. Meyka AI, an AI-powered market analysis platform, will track updates and analyst revisions in real time. These grade-driven views are informational only and not financial advice.
FAQs
What drove the RMD.AX stock move after Q2 earnings?
RMD.AX stock moved on a revenue beat to A$1.422 billion and adjusted EPS A$2.81, with margin improvement and stronger-than-expected device and masks sales cited by analysts.
What is Meyka AI’s forecast for RMD.AX stock?
Meyka AI’s forecast model projects a 12‑month target of A$44.22, implying an upside of 20.11% from the current A$36.82; forecasts are model-based projections and not guarantees.
How is RMD.AX stock valued versus peers?
RMD.AX stock trades at PE 26.00 with ROE 25.13% and a price/book near 0.61, showing premium profitability but mixed valuation metrics versus healthcare peers.
What are the main risks for RMD.AX stock investors?
Key risks include competitive device pricing, reimbursement changes, slower mask adoption, and supply-chain cost pressure that could compress margins and slow revenue growth.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
